Tool: DupCheckTool: DupCheck is a web-based tool to screen for duplicate patients in clinical trials within and across studies, sponsors and therapeutic areas. Please visit our "Tools" page for more information.

Project FlyerProject Flyer

Click here to download 
the NEWMEDS project flyer! 

consortium teaser

Project Office Project Office Annual PGB and WP Leads Meetings Annual PGB and WP Leads Meetings Project Governance Project Governance Funding Mechanisms Funding Mechanisms

  Members Area

IMI | The Innovative Medicines Initiative
EFPIA | European Federation of Pharmaceutical Industries and Associations

Pfizer logo

Pfizer Limited
Ramsgate Rd


Participant's Lead

Sarah Grimwood Sarah Grimwood
Research Fellow, Dept of Psychiatry & Behavioral Disorders, Neuroscience Research Unit, Pfizer 
E-Mail to Sarah Grimwood Contact  

Institute Presentation

Pfizer is a global pharmaceutical company with active programs in Psychiatry areas relevant to this project. Pfizer personnel have expertise in a number of areas that will support this project:
• Expertise in statistical analysis including support vector machine learning and Bayesian approaches
• Expertise in imaging approaches and image analysis
• Expertise in preclinical animal and EEG models and testing
• Expertise in CIAS study design and conduct
• Expertise in pharmacogenomics approaches, including genetic, SNP, and CNV analysis.
Pfizer has vast experience in the imaging  and electrophysiological modalities planned for this project with ongoing and future trials in progress that can provide substrate for the development of the imaging and EEG approaches. Pfizer also has an active clinical sample repository with samples available for use by this project.  Furthermore, Pfizer will provide key data for development of advanced clinical trial methodology focusing on placebo effect and early identification of responders.

17 Pfizer Limited